Tech Company M&A Transactions
Avila Therapeutics Acquisition
Avila Therapeutics was purchased by Celgene. The transaction became public on 1/27/2012. Purchase price was estimated to be $350 million.
Transaction Overview
Company Name
Acquired By
Announced On
1/27/2012
Transaction Type
M&A
Amount
$350,000,000
M&A Terms
Under the terms of the merger agreement, Celgene will acquire Avila Therapeutics, Inc. for $350 million in cash, plus up to $195 million for milestones contingent upon the development and regulatory approval of AVL-292, as well as up to $380 million in potential milestone payments contingent upon the development and approval of candidates generated from the Avilomics platform.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
45 Wiggins Ave.
Bedford, MA 01730
USA
Bedford, MA 01730
USA
Phone
Website
Email Address
Overview
Avila Therapeutics, Inc., is a venture-backed company focused on the discovery and development of novel small molecule therapeutics to address significant unmet clinical needs with an initial focus on cancer and viral diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Katrine Bosley
Chief Scientific Officer
Juswinder Singh
VP - Operations
Nagesh Mahanthappa
Browse more venture capital transactions:
Prev: 1/27/2012: Cozi Group venture capital transaction
Next: 1/27/2012: Joyent venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs